Pantothenic acid (vitamin B5) supplementation in rheumatological diseases: a review

Jozélio Freire de Carvalho; Ana Teresa Amoedo Martinez

doi:10.53941/jmai.2025.100013

Abstract

Background: Pantothenic acid (PA), the dietary precursor of coenzyme A, plays a central role in mitochondrial metabolism, lipid regulation, and the synthesis of steroid hormones and neurotransmitters. Although PA has been traditionally applied in areas such as wound healing and immunomodulation, its potential therapeutic relevance in rheumatology has not been well characterized. Objective: To provide an updated overview of the clinical effectiveness, safety, and research gaps related to PA supplementation in rheumatic diseases. Methods: A structured search was performed across PubMed/MEDLINE, Web of Science, SciELO, and LILACS for human studies published up to July 2024. Eligible articles investigated PA supplementation in patients with rheumatic diseases and reported clinical outcomes. Key data relating to population characteristics, dosage, treatment duration, outcomes, and adverse effects were extracted. Results: Seven studies involving 183 participants were included: two focused on osteoarthritis (OA), one on fibromyalgia (FM), and four addressing systemic lupus erythematosus (SLE). PA was administered using heterogeneous regimens, generally in combination with other micronutrients, at doses ranging from 12.5 mg to 12 g/day and over variable follow-up durations. Clinical improvement was reported in most studies, especially in cutaneous lupus, in which substantial resolution of lesions was frequently observed. Benefits in fatigue in SLE and pain reduction in OA and FM were also noted. Adverse events were rare and predominantly mild. Conclusions: Available clinical evidence suggests that PA supplementation may provide symptomatic benefit in selected rheumatic diseases, with a favorable safety profile. However, current data remain limited by small sample sizes, lack of standardized protocols, and frequent co-supplementation. Well-designed randomized clinical trials—especially in SLE and OA—are required to determine therapeutic efficacy, optimal dosing, and mechanistic pathways.

References

1.
Gheita, A.A.; Gheita, T.A.; Kenawy, S.A. The potential role of B5: A stitch in time and switch in cytokine. Phytother. Res. 2020, 34, 306–314.
2.
Abidin, M.Z.; Saravanan, T.; Zhang, J.; et al. Modular Enzymatic Cascade Synthesis of Vitamin B5 and Its Derivatives. Chemistry 2018, 24, 17434–17438.
3.
Johnson, K.A.; Yao, W.; Lane, N.E.; et al. Vanin-1 pantetheinase drives increased chondrogenic potential of mesenchymal precursors in ank/ank mice. Am. J. Pathol. 2008, 172, 440–453.
4.
Sánchez-Muñoz, F.; Amezcua-Guerra, L.M.; Macías-Palacios, M.; et al. Vanin-1 as a potential novel biomarker for active nephritis in systemic lupus erythematosus. Lupus 2013, 22, 333–335.
5.
Haslock, D.I.; Wright, V. Pantothenic acid in the treatment of osteoarthrosis. Rheumatol. Phys. Med. 1971, 11, 10–13.
6.
Annand, J.C. Osteoarthrosis and Pantothenic Acid. J. Coll. Gen. Pract. 1962, 5, 136–137.
7.
Ali, A.; Njike, V.Y.; Northrup, V.; et al. Intravenous micronutrient therapy (Myers’ Cocktail) for fibromyalgia: A placebo-controlled pilot study. J. Altern. Complement. Med. 2009, 15, 247–257.
8.
Leung, L.H. Systemic lupus erythematosus: A combined deficiency disease. Med. Hypotheses 2004, 62, 922–924.
9.
Welsh, A.L. Lupus erythematosus treatment by combined use of massive amounts of calcium pantothenate or panthenol with synthetic vitamin E. AMA Arch. Dermatol. Syphilol. 1952, 65, 137–148.
10.
Goldman, L. Intensive panthenol therapy of lupus erythematosus. J. Investig. Dermatol. 1950, 15, 291–293.
11.
Goldman, L. Treatment of subacute and chronic discoid lupus erythematosus with intensive calcium pantothenate therapy. J. Investig. Dermatol. 1948, 11, 95.
12.
Tufts, M.; Bunde, C.A. Therapeutic advantages of the addition of calcium pantothenate to salicylates in the oral treatment of rheumatoid arthritis. Am. Pract. Dig. Treat. 1953, 4, 755–756.
13.
Buck, M.D.; O’Sullivan, D.; Klein Geltink, R.I.; et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell 2016, 166, 63–76.
14.
Sena, L.A.; Li, S.; Jairaman, A.; et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 2013, 38, 225–236.
15.
Buck, M.D.; O’Sullivan, D.; Pearce, E.L. T cell metabolism drives immunity. J. Exp. Med. 2015, 212, 1345–1360.
16.
Slepyan, A.H.; Frost, D.V.; Overby, L.R.; et al. The diagnosis of lupus erythematosus; probable significance of pantothenate blood levels. AMA Arch. Dermatol. 1957, 75, 845–850.
17.
Gominak, S.C. Vitamin D deficiency changes the intestinal microbiome, reducing B vitamin production in the gut. The resulting lack of pantothenic acid adversely affects the immune system, producing a “proinflammatory” state associated with atherosclerosis and autoimmunity. Med. Hypotheses 2016, 94, 103–107.
18.
Ambanelli, U.; Rosati, G.F. Blood concentrations of pyridoxine and pantothenic acid in rheumatoid arthritis. Reumatismo 1971, 23, 76–79.
19.
Wang, Z.; Liu, J.Q.; Xu, J.D.; et al. UPLC/ESI-QTOF-MS-based metabolomics survey on the toxicity of triptolide and detoxication of licorice. Chin. J. Nat. Med. 2017, 15, 474–480.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us